drugset
drugset / Trial / NCT04480957

Ascending Dose Study of Investigational SARS-CoV-2 Vaccine ARCT-021 in Healthy Adult Subjects

NCT04480957 ↗

Phase 1/2 Completed 106 enrolled Arcturus Therapeutics, Inc.
RandomizedParallel-groupDouble-blindTreatment

Summary

Determine safety and tolerability and immungenicity of investigational vaccine ARCT-021 in healthy adult volunteers.

Timeline

Start
2020-08-04
Primary completion
2021-01-29
Completion
2021-01-29

Drugs

EvaluationDrugModalityDoseRoute
Subject ARCT-021 Messenger RNA (mRNA) — Intramuscular

Indications

Orthocoronavirinae infectious disease